Knight Therapeutics Reports Fourth Quarter and Year-End 2025 Results
Executive Summary
- Knight Therapeutics reported FY 2025 revenue of $450.1 M (up 21% YoY) and Adjusted EBITDA of $73.1 M (up 26% YoY), delivering record‑high cash flow from operations of $68.96 M.
- The company provided FY 2026 guidance of $490–$510 M revenue and adjusted EBITDA margin of ~15%, indicating a material positive outlook.
- Significant corporate actions included the Paladin and Sumitomo acquisitions, a US$100 M revolving credit facility (with an additional US$100 M accordion), multiple product approvals/launches across Canada and Latin America, and share repurchases under its NCIB.
Key Details
- Financial Performance – FY 2025
- Revenues: $450,088 K (+21% YoY).
- Gross margin: 44% of revenue (down from 47%).
- Operating loss: $2,350 K vs. operating income of $7,397 K in 2024.
- Net loss: $5,374 K vs. net income of $4,332 K in 2024.
- Adjusted EBITDA: $73,056 K (+26% YoY).
- Adjusted EBITDA per share: $0.74 (up $0.16 YoY).
-
Cash flow from operations: $68,957 K (+90% YoY).
-
Guidance – FY 2026
- Revenue target: $490–$510 M.
-
Adjusted EBITDA margin: ~15% of revenue.
-
Acquisitions & Transactions
- Paladin Pharma acquisition (June 2025): Purchase price $90,002 K + $23,008 K inventory; additional holdback $8,457 K payable; contingent up‑to US$15 K on sales milestones.
- Sumitomo license & asset purchase (June 2025): Up‑front $25,400 K; contingent up‑to US$15,750 K on milestones.
-
NCIB: Launched Aug 2025 to buy up to 3 M shares over 12 months; 1,130,600 shares purchased at avg. $5.69 (cash $6,431 K). Additional purchases up to March 12 2026: 1,183,300 shares at avg. $6.17 (cash $7,296 K).
-
Financing
- Secured US$100 M revolving credit facility with four lenders; accordion feature for an additional US$100 M.
- Closed working‑capital line of credit with Citibank.
- Settled Synergy loan: cash receipt $13,758 K (US$10 K) plus warrants valued at $1,116 K (US$811 K).
-
Collected strategic loan receivable: $3,840 K (US$2,771 K).
-
Product & Regulatory Updates
- Launched/approved 10 products in Q4‑25 across Canada/LATAM (e.g., Minjuvi® in Argentina, Pemazyre® in Brazil/Mexico, Bapocil® in Colombia).
- Submitted Niktimvo® for Brazil approval (Q1‑26) and supplemental Minjuvi® indications in Argentina & Mexico.
- Received Health Canada notice of non‑compliance for Qelbree®; response planned for 2026.
-
ANVISA rejected Tavalisse® marketing application; appeal accepted.
-
Balance Sheet Highlights (Dec 31 2025)
- Cash & equivalents: $95,283 K (down 33% YoY).
- Inventories: $135,866 K (+32%).
- Intangible assets: $379,510 K (+34%) – largely from Paladin and Sumitomo acquisitions.
-
Bank loans: $67,895 K (+56%) reflecting drawdown of revolving facility.
-
Operating Metrics
- Debt‑to‑Adjusted EBITDA leverage improved to <1x (from >1.5x Q3‑25).
-
Net cash position increased from net debt of $1 M (Q3‑25) to net cash of $27 M (year‑end 2025).
-
Conference Call
- Date: Thursday, March 19 2026, 8:30 a.m. ET.
Notable Quotes
“We delivered another year of record‑high adjusted revenues and EBITDA while strengthening our Canadian infrastructure and portfolio… Our guidance reflects confidence in delivering nearly $500 M revenue within the next two to three years.” – Samira Sakhia, President & CEO
Materiality Assessment: Material – Positive (record financial performance, forward‑looking guidance, and significant acquisitions/financing).